BSE Live
Apr 21, 14:50Prev. Close
2015.65
Open Price
2014.80
Bid Price (Qty.)
1999.00 (1)
Offer Price (Qty.)
2004.70 (1)
NSE Live
Apr 21, 14:50Prev. Close
2014.90
Open Price
2029.00
Bid Price (Qty.)
2000.00 (237)
Offer Price (Qty.)
2002.70 (1)
| Profit & Loss account of RPG Life Sciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 647.54 | 577.48 | 509.08 | 440.16 | 382.88 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 647.54 | 577.48 | 509.08 | 440.16 | 382.88 | |
| Total Operating Revenues | 653.43 | 582.05 | 512.81 | 440.16 | 389.14 | |
| Other Income | 12.68 | 7.21 | 4.80 | 2.99 | 0.91 | |
| Total Revenue | 666.11 | 589.26 | 517.61 | 443.15 | 390.05 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 110.26 | 120.65 | 86.12 | 88.13 | 85.75 | |
| Purchase Of Stock-In Trade | 95.14 | 61.18 | 92.05 | 78.90 | 50.36 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 8.61 | 2.70 | -7.30 | -25.21 | -5.01 | |
| Employee Benefit Expenses | 126.14 | 132.15 | 117.06 | 99.97 | 94.66 | |
| Finance Costs | 0.62 | 0.45 | 0.31 | 0.52 | 0.79 | |
| Depreciation And Amortisation Expenses | 21.43 | 17.07 | 15.50 | 15.66 | 16.47 | |
| Other Expenses | 153.63 | 137.22 | 122.19 | 112.01 | 93.45 | |
| Total Expenses | 515.83 | 471.42 | 425.93 | 369.98 | 336.47 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 150.28 | 117.84 | 91.68 | 73.17 | 53.58 | |
| Exceptional Items | 82.60 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 232.88 | 117.84 | 91.68 | 73.17 | 53.58 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 49.69 | 32.54 | 24.35 | 22.76 | 17.15 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -0.05 | -2.36 | -0.31 | -1.07 | -3.57 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 49.64 | 30.18 | 24.04 | 21.69 | 13.58 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 183.24 | 87.66 | 67.64 | 51.48 | 40.00 | |
| Profit/Loss From Continuing Operations | 183.24 | 87.66 | 67.64 | 51.48 | 40.00 | |
| Profit/Loss For The Period | 183.24 | 87.66 | 67.64 | 51.48 | 40.00 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 | |
| Diluted EPS (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 26.46 | 19.85 | 15.88 | 11.91 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 300.00 | 200.00 | 150.00 | 120.00 | 90.00 |
28.01.2026
RPG Life Consolidated December 2025 Net Sales at Rs 180.03 crore, up 4.24% Y-o-Y
28.01.2026
RPG Life Standalone December 2025 Net Sales at Rs 180.03 crore, up 4.24% Y-o-Y
20.10.2025
RPG Life Standalone September 2025 Net Sales at Rs 181.68 crore, up 5.5% Y-o-Y
28.07.2025
RPG Life Standalone June 2025 Net Sales at Rs 168.92 crore, up 2.12% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth